IRWD Stock — Ironwood Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$4.36

Market cap

$720.4M

Cash

$79.1M

Enterprise value

$840.8M

Balance sheet

Cash	$79.1M
Debt	$199.5M
Net cash	-$120.4M
Enterprise value	$840.8M
Basic shares	165.2M shares
Fully diluted shares	181.9M shares
Fully diluted market cap	$793.1M
Cash per share	$0.48

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IRWD daily closes…

Loading price history…

Pipeline assets

LINZESS

Approved · Active Modality: oral peptide (guanylate cyclase-C agonist)

Target guanylate cyclase-C (GC-C)

Partnerships AbbVie: US co-development/commercialization collaboration (Ironwood records its share of LINZESS net profit/loss); ex-US partners market as LINZESS/CONSTELLA

Indications

irritable bowel syndrome with constipation (IBS-C) (Approved)
chronic idiopathic constipation (CIC) (Approved)

Status note Linaclotide; first FDA-approved GC-C agonist class. Majority of company revenue from US LINZESS sales; pediatric linaclotide programs referenced but undescribed.

Apraglutide

Phase 3 · Active Modality: synthetic peptide analog (long-acting)

Target GLP-2

Partnerships VectivBio (acquired): origin; Asahi Kasei Therapeutics (AKTX): exclusive license for apraglutide in Japan (2022)

Indications

short bowel syndrome with intestinal failure (SBS-IF) (Phase 3)

Status note Next-generation long-acting synthetic peptide analog of GLP-2 for SBS patients dependent on parenteral support; confirmatory Phase 3 trial recruiting.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05796388	Not disclosed	Recruiting	Collaborator	Mayo Clinic	ABBV	Irritable Bowel Syndrome With Constipation	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Mayo Clinic on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

IRWD — Ironwood Pharmaceuticals Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials